J. Taubert
Equibles does not estimate personal net worth.
Get an email with a short summary when Johnson & Johnson publishes a filing, an earnings call transcript or a press release.
Get JNJ alertsAbout J. Taubert
The proxy statement of Johnson & Johnson reports total compensation of $14,030,063 for J. Taubert in fiscal 2025, including a base salary of $1,220,308. Disclosed compensation is on record for 6 fiscal years. Johnson & Johnson is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Johnson & Johnson includes J. Wolk (CFO), D. E. Pinto (Board Member), Daniel Pinto (Board Member) and 7 others.
Affiliation history
-
Johnson & Johnson (JNJ)
Proxy statement
Current
Company network
Leadership on record at Johnson & Johnson
- J. Wolk CFO
- D. E. Pinto Board Member
- Daniel Pinto Board Member
- Darius Adamczyk Board Member
- Dr. Nadja West Board Member
- E. A. Woods Board Member
- Eugene A. Woods Board Member
- H. Joly Board Member
- J. A. Doudna Board Member
- J. Duato Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Johnson & Johnson (JNJ) | EVP, WWC Innovative Medicine | $1,220,308 | $14,030,063 |
| 2024 | Johnson & Johnson (JNJ) | EVP, WWC Innovative Medicine | $1,192,308 | $11,190,045 |
| 2023 | Johnson & Johnson (JNJ) | EVP, WWC Innovative Medicine | $1,130,000 | $10,995,394 |
| 2022 | Johnson & Johnson (JNJ) | EVP, WWC Innovative Medicine | $1,008,462 | $8,781,532 |
| 2021 | Johnson & Johnson (JNJ) | EVP, WWC Innovative Medicine | $938,077 | $10,225,759 |
| 2020 | Johnson & Johnson (JNJ) | EVP, Worldwide Chair Pharmaceuticals | $884,615 | $9,532,469 |
Recent activity
No call appearances or filed executive changes recorded yet.